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loblastomaWHO IV. Using immunohistochemical marker beta catenin and
histology 43 tumours were subdivided into WNT (26), SHH (13), non-
WNTnonSHH (4) groups.
Conclusion: There was an obvious male predominance in this group. 78%
of cases were diagnosed within 3 months of onset of symptoms. 57% of
cases had high risk disease.ST-1_V1.5
INFLAMMATORY MYOFIBROBLASTIC TUMORS: A TALE OF THREE
STORIES
J.H. Teo, M.Y. Chan, D.W.Q. Lian, R. Bhattacharyya, P. Iyer. Haematology and
Oncology Service, Department of Paediatric Subspecialties, KK Women's and
Children's Hospital, Singapore
Background/Objectives: Inﬂammatory myoﬁbroblastic tumors (IMT)
are unusual intermediate malignant potential tumors that occur in soft
tissues and visceral organs of children and young adults. The tumors
consist of myoﬁbroblastic spindle cells and inﬂammatory cells. These
tumors can be locally aggressive, recur or rarely metastasize. There are
no clear consensus guidelines on treatment for patients with such tu-
mors. We describe three cases from our tertiary academic paediatric
institute in Singapore.
Design/Methods: A retrospective analysis of paper, electronic records, and
histology slides of patients diagnosed with IMT in our hospital between
1997-2012 was performed.
Results: Three patients with IMT were identiﬁed. All patients had intra-
abdominal tumors (omentum, spleen, supra-renal) with one patient also
having a concurrent IMT located in the left hemi thorax. Histopathological
ﬁndings reported positivity for ALK -1 stain in 2 patients. Primary com-
plete surgical resection of the tumors was attempted without success.
And hence adjuvant chemotherapy was administered in all cases. A va-
riety of chemotherapeutic agents in combinations were used as per
physician preference. Two patients also received monotherapy with non-
steroidal anti-inﬂammatory drug (NSAID) when the tumors did not
respond to chemotherapy. Both the patients on NSAID therapy showed
transient partial responses. One patient with aggressive IMT died due to
neutropenic sepsis. The mTOR inhibitor sirolimus was started on one
patient who is now alive with stable disease three years after
commencement. A local recurrence in one patient was treated with
further surgery and she now remains in complete remission. These two
patients remain on active follow up.
Conclusion: Sirolimus appears to offer disease control in children with
inoperable or resistant IMT. Further studies are required to understand and
manage these fascinating mesenchymal tumors better.ST-1_V1.6
OUTCOMES OF SURGERY FOR RENAL TUMOURS WITH INTRAVASCULAR
EXTENSION
M. Bhagat, S. Qureshi, S. Kembhavi, T. Vora, M. Ramadwar,
G. Chinnaswamy, S. Laskar. Tata Memorial Hospital, Mumbai, India
Aim: The aim of this study was to review themanagement of childrenwith
Wilms' tumour who had intravascular thrombus.
Material and methods: The data regarding presentation, treatment
received, surgical management, complications and outcomes were evalu-
ated. All patients received neoadjuvant chemotherapy except in two.
Results: The study cohort included 31 patients with intravascular
thrombus treated from 2006 to 2015. The thrombus extent at presentation
was: Infrahepatic inferior vena cava (IVC) -19, retrohepatic IVC -6, supra-
hepatic IVC -1 and Atrium -5. There was complete clearance of IVC in 11/31
patients with neoadjuvant chemotherapy. Regression of the thrombus
occurred in 17/31 patients. Due to regression of the tumor thrombus from
the atrium, cardiopulmonary bypass could be avoided in 2 patients. In all
patients the thrombus had to be dissected off from the tunica intima due todense ﬁbrosis around it. The only major complication was massive
bleeding in one patient with atrial thrombus. There was no perioperative
or 30-day postoperative mortality. The 3-year OS and EFS was 89.3% and
77.8% respectively.
Conclusions: Intravascular tumor thrombus extension has favourable
outcomes after contemporary multidisciplinary treatment. Chemotherapy
aids in surgery, with tumor regression and thus may obviate the need of
cardiopulmonary bypass in atrial thrombus.ST-1_V1.7
PEDIATRIC MEDULLOBLASTOMA: EXPERIENCE AT TATA MEDICAL
CENTER, KOLKATA
Anirban Das, Rimpa Basu Achari, Shekhar Krishnan, Lateef Zameer, Aditi
Chandra, Mayur Parihar, Arpita Bhattacharyya. Tata Medical Center,
Kolkatta, India
Background: Medulloblastoma is the commonest pediatric malignant
brain tumor. Cure-rates of ~75% have been achieved in the West. Indian
centers have reported inferior survival. The aim of the studywas to analyze
the clinical proﬁle and outcome in children treated at a new referral cancer
hospital in Eastern India.
Methods: A retrospective analysis of case records of children (<18-
years) diagnosed with medulloblastoma, between June 2011-July 2016,
was performed. Modiﬁed Chang staging, using MRI of brain and spine,
and analysis of cerebrospinal ﬂuid was used. Children aged >3-years,
with post-operative residual tumor <1.5cm2, M0 stage, and non-large
cell/anaplastic histology, were classiﬁed as ‘standard-risk.’ ‘Standard-
risk’ and ‘high-risk’ children received cranio-spinal irradiation with
23.4Gy in 13 fractions, and 36Gy in 20 fractions, over 3.5-4 weeks,
respectively. Posterior fossa and/or tumor bed was boosted to a total
dose of 55.8Gy in 31 fractions. Following radiation, ‘standard-risk’
children received 8 cycles of cisplatin, lomustine and vincristine. ‘High-
risk’ patients received 8 cycles of cisplatin, cyclophosphamide and
vincristine, or, ifosfamide, cisplatin and etoposide (physician's discre-
tion). Analysis was performed using IBM-SPSSv20. Kaplan-Meier
method was used for survival analysis.
Results: Twenty-six children were enrolled. Median age was 6-years
(range:0.9-13.5); 4 (15.3%) were 3-years at diagnosis. 54% were males.
Median symptom-interval was 3.7-months (range: 1-12). Symptoms
included vomiting (20; 77%), headache (17; 65%), unsteadiness (14; 54%)
and cranial nerve palsy (2; 7%). Location of tumor (n¼22) included
midline, cerebellum (9; 41%), lateral cerebella (5; 23%) and roof of 4th
ventricle (8; 36%). Modiﬁed Chang staging: T (n¼17): T1 (1; 6%), T2 (2;
12%), T3 (5; 29%), T4 (9; 53%), and, M (n¼22): M0 (9; 41%), M1 (3; 13.5%),
M3 (7; 32%), M4 (3; 13.5%).
Seven (32%) childrenwere standard-risk and 15 (68%) were high-risk; data
was missing for the rest. Eight (31%) refused treatment. Extent of surgical
resection (n¼16) included gross total resection: 7 (44%), near total resec-
tion: 3 (18.5%), sub-total resection: 6 (37.5%). A ventriculo-peritoneal shunt
had been inserted in 11/20 (55%). Median time from surgery to initiation of
radiotherapy was 41-days (range:34-51).
At a median follow-up of 28.5-months (range:0.1-55), 12 (46.5%) were
alive, 9 (35%) of whom had completed, and 3 (11.5%) were on treatment; 3
(11.5%) had relapse/progression, 2 (7.5%) had abandoned treatment, while
1 (3.5%) had received palliative care. Among the 4 children3-years, 1 had
disease progression and 3 refused treatment. 4-year EFS (for those who
completed therapy was 66.1 ± 1.2%; standard-risk: 100%, high-risk: 45 ±
1.8%. Treatment-related complications included posterior fossa syndrome
(7; 39%), sepsis (4; 22%), shunt obstruction (1; 5%) and hearing loss (4;
22%).
Conclusion: Limitations of the study included high prevalence of treat-
ment-refusal/abandonment (10; 38%) and non-availability of molecular
subtyping for more accurate risk stratiﬁcation. Nevertheless, this study
shows that when properly diagnosed and treated, the outcomes of chil-
drenwith standard risk medulloblastoma in India are comparable with the
west. Further improvements in outcome require providing social support
to reduce treatment-refusal/abandonment, standardization of care for
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CLINICAL EXPERIENCE OF GRANULOCYTE TRANSFUSION THERAPY IN
MANAGEMENT OF NEUTROPENIA RELATED INFECTIONS IN A
TERTIARY CARE CENTER
Sohini Chakraborty, Ruchi Chaudhary, Waseem Iqbal, Sonamani
Ngangbam, Shobha Badiger, Tadele Hailu, B.R. Prathip, Sharat
Damodar, K.S. Nataraj, Sunil Bhat. Mazumdar Shaw Cancer Center,
Narayana Health City, Bangalore, India
E-mail address: sunilbhat_9@hotmail.com (S. Bhat).
Background: Granulocyte transfusions have recently gained popularity for
the treatment of severe infections in neutropenic patients which do not
respond to conventional antimicrobial therapies and recombinant growth
factors. We conducted the present study to determine the clinical course of
patients with neutropenia related infection receiving granulocyte trans-
fusions in our center and to assess its efﬁcacy in resolution of infections.
Methods: Retrospective analysis of all pediatric patients up to 18 years of
age with neutropenia and infection receiving granulocyte transfusions in
our hospital between January 2015 and July 2016.
Results: Twenty one pediatric patients with severe neutropenia related
infections unresponsive to appropriate antimicrobial agents were included
in the study. They received a total of 57 granulocyte transfusions. The study
population comprised of 10 females (47.6%) and 11 males (52.4%). Median
age of the study population was 9 yrs (5 months-16 years). 13 patients
suffering from nonmalignant hematological diseases and 8 patients with
malignant diseases were included in the study population. Voluntary
healthy donors were used after granulocyte mobilization using gran-
ulocyte colony- stimulating factor (G-CSF) and dexamethasone. The me-
dian donor WBC count before leukapheresis was 31.9  109 /L and the
mean donor granulocyte yield was 8.9  1010 /L. Seven patients had
localized infection while 14 had sepsis. Causative organisms could be
isolated in 16 cases out of which gram negative bacillus was isolated in 15
(93.75%). Median duration of neutropenia, antimicrobial therapy and G-
CSF administration before granulocyte transfusion was 11 days (range 2-
34), 10 days (range 3-20) and 9 days (range 2-20) respectively. Patients
received amean of 2.85 (range 1-8) granulocyte transfusions andmean cell
dose of 2.7  1010 granulocytes. Ten of the total twenty one patients
included had a favorable response and recovered from the infection.
Granulocyte transfusions were generally well tolerated inmost of the cases
except for one episode of transfusion associated acute lung injury.
Conclusion: Granulocyte transfusions seem to be a clinically useful and
generally safe adjunct in management of severe neutropenia related
infections.
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BLOOD AND BLOOD PRODUCTS TRANSFUSION AUDIT: CURRENT
PRACTICES AND LACUNAE IN BLOOD AND BLOOD PRODUCT
TRANSFUSION AMONG HOSPITALIZED CHILDREN
Purva Kanvinde, Mukesh Agrawal. Seth G S Medical College and KEM
Hospital, India
Transfusion audits are most effective tools to detect inappropriate blood
product transfusion practices and suggest remedial measures to ensure
safe and effective use of this precious product in health-care.
Objectives: Present study was designed to assess current practices
regarding blood product transfusions in childrenwith special emphasis on
the appropriateness of these transfusions.
Materials & Method: Present study was a prospective study conducted
over a period of 22 months from January 2013 to October 2014. Each
episode of transfusion was analyzed and divided into appropriate and
inappropriate according to the type of blood component, the clinical and
hematological indication. Data was reviewed according to British Com-
mittee for Standards in Hematology and American Association of Blood
Bank guidelines.Results: In this study, a total 741 transfusions were used in 327 cases,
including 449 packed red blood cells (60.6%), 148 Fresh frozen plasma
(20.0%), 140 (18.9%) platelets and 4 (0.5%) whole blood transfusions.
Appropriate usage of blood and blood products was 70.5%. Most inap-
propriately used was FFP (39.2% of FFP transfusions), followed by Packed
RBCs (28.7%) and Platelets (22.9%). Packed RBCs transfusions were used
most commonly for sepsis with/without DIC (25.2%), followed by nutri-
tional anemia (20.7%) Packed RBC transfusions were used most inappro-
priately for nutritional anemia (49.5%) and sepsis (46.9%). FFP transfusions
were used maximally for the indication of sepsis with/without DIC (43.2%),
followed by perioperative indications (21.6%). FFP transfusions were most
inappropriate for Dengue (68.8%) and perioperative indications (53.1%).
Platelet transfusions were most commonly used for Aplastic anemia (45%)
followed by sepsis (24.3%) Platelet transfusions weremost inappropriate in
Dengue cases (85%) and Idiopathic thrombocytopenic purpura (50%).
Conclusion: Present study concludes that in the study population, about
one-third of all blood component transfusions used in study center are
inappropriate. This study suggests establishment of set protocols for
requisition of blood component transfusions in the study set-up to mini-
mize irrational and unsafe use of these products.
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FUNGAL BRAIN ABSCESS IN HAEMATOLOGICAL MALIGNANCY: IS GOOD
OUTCOME POSSIBLE?
Richa Jain 1, Amita Trehan 1, M.R. Shivaprakash 2, Arunaloke
Chakrabarti 2, Kanchan Mukharjee 3, Deepak Bansal 1, Pratibha
Singhi 4. 1 Pediatric Hematology and Oncology Unit, Advanced Pediatric
Centre, USA; 2Department of microbiology; 3Department of Neurosurgery;
4 Pediatric Neurology unit, Advanced Pediatric Centre, Postgraduate
Institute of Medical Education and Research, Chandigarh, India
Introduction: Incidence of invasive fungal infections in children with
hematological malignancies is increasing. We present clinical features and
outcome of children with fungal brain abscess in acute lymphoblastic
leukemia (ALL), an entity which traditionally has dismal outcomes.
Methods: Eighteen months data is presented. Total 160 new ALL patients
were recruited. Thirteen developed proven fungal infection. Details of
children with fungal CNS infection were retrieved and analyzed.
Results: Five children had fungal brain abscesses. B-cell ALL:T-cell was 4:1.
Three childrenwere standard risk, 2 intermediate risk. All were on intense
chemotherapy including steroids; 4 induction, 1 intensiﬁcation. Clinical
presentation: Prolonged neutropenia: 100%; fever: 100%; altered senso-
rium/seizures seen in 80% (4/5). Duration of neutropenia: 16 days (14-23).
Primary focus was lung in 4, ear in 1. Brain abscess was single in 2, multiple
in 3 children. Meningitis was present in 2. All children underwent surgery
(burr-hole drainage:4, excision:1). Culture/PCR proven fungus was seen in
all: Aspergillus in 4; Mucor:1. Elevated serum galactomannan seen in 66%.
Combination antifungals were given for aspergillus: Amptotericin (plain/
liposomal)& voriconazole for 10 days, followed by voriconazole alone for 6
months. Single mucor patient received amphotericin for 12 months.
Overall survival at 10 months: 80%; event free survival: 40% (events-
death:1, defaulter:1, cortical blindness:1). Three children are continuing
chemotherapy.
Conclusion: Mortality rate in fungal brain infections in children is re-
ported to be 65%. Better outcomes in our patients can be attributed to
multimodality therapy and early initiation of antifungal therapy along
with judicious management of chemotherapy.
Keywords: Aspergillus, acute lymphoblastic leukemia, brain abscess,
invasive aspergillosis
